Insulet Corporation (NasdaqGS:PODD), a company specializing in medical devices for insulin-dependent diabetes, has been added to the Russell 2500 Grow...
Neutral
The article provides a financial overview of Insulet Corporation (NASDAQ: PODD), specifically focusing on its forward price-to-sales ratio. It briefly...
Neutral
This article provides financial information for Insulet Corporation (NASDAQ: PODD), specifically focusing on its price to earnings forward. It appears...
This article provides financial information for Insulet Corporation (BMV:PODD), specifically its price to sales forward metric. The data is available ...
Neutral
Insulet Corporation has appointed Jonathan “Jay” Mazelsky to its Board of Directors, signaling a strategic focus on operational execution and long-ter...
Bullish
Insulet Corporation released new clinical results for its Omnipod 6 and a fully closed-loop (FCL) system for type 2 diabetes, showing significant impr...
Bullish
Bank of America Securities has reiterated its "Buy" rating on Insulet Corporation (PODD), setting a price objective of $208.00. The analyst's assessme...
Neutral
Truist Securities has lowered its price target for Insulet Corporation (NASDAQ:PODD) to $219 from $250, while maintaining a Buy rating. The valuation ...
Insulet recently presented new clinical data on its Omnipod 6 and fully closed-loop system for type 2 diabetes, showing improved glucose control and p...
Bearish
Insulet is recalling approximately 7 million Omnipod Pods globally due to a manufacturing defect that can cause insufficient insulin delivery, potenti...
Bullish
Insulet released new clinical data supporting its Omnipod 6 and future fully closed-loop (FCL) automated insulin delivery (AID) systems. The STRIVE tr...
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Insulet Corporation (GOV). It provides a detailed table including fund nam...
Bullish
Insulet Corporation announced new clinical results for its Omnipod® 6 and fully closed-loop (FCL) system for type 2 diabetes, presented at the America...
Insulet Corporation announced new clinical data from the STRIVE pivotal trial and EVOLUTION 3 feasibility study, demonstrating significant improvement...
Neutral
Insulet Corporation (PODD) stock is showing an uptrend despite a recent voluntary global medical device correction affecting millions of pods due to a...
Insulet's Independent Chair, Elizabeth Weatherman, recently purchased US$497k worth of company stock at US$144 per share, increasing her holding by 66...
Bullish
Insulet Corporation announced its plans for the American Diabetes Association's 86th Scientific Sessions, highlighting new data and innovations for it...
Bullish
Insulet Corporation announced its plans for the American Diabetes Association's 86th Scientific Sessions, where it will showcase new data and innovati...
Bullish
Insulet Corporation has launched significant enhancements for its Omnipod 5 Automated Insulin Delivery (AID) System, including a new 100 mg/dL target ...
Bullish
Insulet has launched new algorithm enhancements for its Omnipod 5 automated insulin delivery system, including a 100 mg/dL Target Glucose option for g...